PRECEPTORSHIP PROGRAMME

Lymphoma
Malignant lymphomas
Modern classification and
management of the most
frequent entities

LUGANO
SWITZERLAND

3-4 NOVEMBER 2017

Co-Chairs  Michele Ghielmini, CH
            Martin Dreyling, DE
ESMO PRECEPTORSHIP PROGRAMME
LYMPHOMA

Malignant lymphomas
Modern classification and management of the most frequent entities

Lugano, Switzerland
3-4 November 2017

CO-CHAIRS:  Michele Ghielmini, Switzerland
              Martin Dreyling, Germany

SPEAKERS:    Elias Campo, Spain
              Massimo Federico, Italy
              Martin Hutchings, Denmark
              Silvia Montoto, United Kingdom
              Leticia Quintanilla-Fend, Germany
              Lena Specht, Denmark

LEARNING OBJECTIVES

• To highlight the pathological bases of the most recent lymphoma classification
• To understand the role of PET in staging, re-staging and follow-up
• To review the treatment strategy for the most common lymphoma types
• To dissect the peculiarities of lymphomas arising in particular extranodal sites
• To illustrate special and innovative treatment strategies
• To discuss clinical cases between faculty and participants

ACCREDITATION

The programme of this event has been accredited with 10 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org
# Friday, 3 November 2017

## 08:45-09:00
**15’** Opening and welcome

- **15’** Welcome from ESMO, objectives and scientific introduction
  - Michele Ghielmini, CH

## 09:00-10:40
**100’** SESSION 1 Pathology and staging

- **30’** The history of lymphoma classification and the 2016 WHO revision
  - Elias Campo, ES
- **20’** Methods used to diagnose lymphoma
  - Leticia Quintanilla-Fend, DE
- **20’** Role of PET in staging and treatment of lymphomas
  - Martin Hutchings, DK
- **2x15’** 2 x Participant clinical case discussion
  - Faculty

### 10:40-11:10
Coffee break

## 11:10-12:40
**90’** SESSION 2 Indolent

- **20’** Pathology of the indolent lymphoid neoplasms
  - Elias Campo, ES
- **20’** Treatment of follicular lymphoma
  - Michele Ghielmini, CH
- **20’** Treatment of chronic lymphocytic leukemia
  - Martin Dreyling, DE
- **2x15’** 2 x Participant clinical case discussion
  - Faculty

### 12:40-14:00
Lunch

## 14:00-15:30
**90’** SESSION 3 Aggressive

- **20’** Pathology of aggressive lymphomas
  - Leticia Quintanilla-Fend, DE
- **20’** Treatment of DLBCL
  - Michele Ghielmini, CH
- **20’** Lymphoma in HIV+ patients
  - Silvia Montoto, UK
- **2x15’** 2 x Participant clinical case discussion
  - Faculty

### 15:30-16:00
Coffee break

## 16:00-17:30
**90’** SESSION 4 Mantle cell and extranodal

- **20’** Management of mantle cell lymphoma
  - Martin Dreyling, DE
- **20’** MALT lymphoma
  - Silvia Montoto, UK
- **20’** CNS lymphoma
  - Michele Ghielmini, CH
- **2x15’** 2 x Participant clinical case discussion
  - Faculty

### 17:30-18:00
SESSION 5 Q&A session

- Faculty

### 19:30
Dinner
**Saturday, 4 November 2017**

<table>
<thead>
<tr>
<th>08:30-10:00</th>
<th>SESSION 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>90'</td>
<td>Hodgkin</td>
</tr>
<tr>
<td>20’</td>
<td>Treatment of early stage</td>
</tr>
<tr>
<td>20’</td>
<td>Treatment of advanced stage</td>
</tr>
<tr>
<td>20’</td>
<td>Prevention and screening of long term side effects</td>
</tr>
<tr>
<td>2x15’</td>
<td>2 x Participant clinical case discussion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:00-10:30</th>
<th>Coffee break</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>10:30-12:00</th>
<th>SESSION 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>90'</td>
<td>T-cell lymphomas and special treatments</td>
</tr>
<tr>
<td>20’</td>
<td>New drugs for lymphoma</td>
</tr>
<tr>
<td>20’</td>
<td>The role of radiotherapy in lymphoma in 2017</td>
</tr>
<tr>
<td>20’</td>
<td>Systemic T-cell lymphomas</td>
</tr>
<tr>
<td>2x15’</td>
<td>2 x Participant clinical case discussion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12:00-12:30</th>
<th>SESSION 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>30’</td>
<td>Q&amp;A session and closing remarks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12:30-13:15</th>
<th>Lunch</th>
</tr>
</thead>
</table>

**Note:** Each 15 minute slot for clinical case discussion includes 7’ case presentation plus 8’ Q&A / panel discussion